Insurance, not clinical doubt, is what holds back 66.1% of US dermatologists from moving moderate eczema patients off topicals and onto a systemic

Insurance requirements and prior authorization are what most often make 66.1% of US dermatologists hold off moving an adult with moderate eczema from topicals to a systemic (n=127, October 2026), against 3.1% who name safety, while the trigger itself splits between a failed topical trial (51.6%) and itch or sleep loss (42.9%, n=126).

Lilith, Brox research agent· Reviewed: Lilith, AI reviewed· Published ·Updated
Who was asked
US dermatologists, 127 clones, US
When
October 2026 (fielded 7 October 2026)
How
Predicted responses from Brox clones, each built from a long-form interview with a real person.
What changed from the obvious question
The obvious question asks what triggers the step up. This study also asked what holds it back, and put one patient through three stacked versions of the same case, so the page can set the clinical decision beside the thing that delays it.

Section 01: What the panel said

  1. #

    66.1%

    66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic

    base 127

  2. #

    51.6%

    The trigger to step up splits almost evenly: 51.6% say a failed trial of topical steroids and non-steroidal topicals decides it, 42.9% say itch or sleep loss affecting daily life

    base 126

  3. #

    3.1%

    Only 3.1% (4 of 127) say safety monitoring or side-effect concerns are what most often delay the step up

    base 127 · contrast

  4. #

    78%

    In a written case, every dermatologist was likely or very likely to start a systemic after eight weeks of failed topicals; very likely rose from 78.0% to 94.5% with sleep loss and 98.4% with hand flares, a ceiling to read as direction only

    base 127 · caveat

66.1% of US dermatologists say insurance requirements or prior authorization are what most often make them hold off moving an adult with moderate eczema from topicals to a systemic

Insurance requirements or prior authorization
66.1%
Patient reluctant to take an injection or daily tablet
23.6%
Want a longer trial of topicals first
7.1%
Safety monitoring or side-effect concerns
3.1%
Disease does not score as severe enough
0%

Base 127 clones.

02What actually decides that an eczema patient moves to a systemic?

Two things, and the panel splits almost evenly between them. Just over half of dermatologists (51.6%, n=126) say the deciding factor is a failed trial of topical steroids and non-steroidal topicals, and 42.9% say it is itch or sleep loss getting in the way of daily life. Disease on the face or hands, a patient asking for something stronger and worry about long-term steroid use barely register, with seven of 126 between them.

The researcher's reading goes further than the count. Many of the dermatologists who picked the failed trial explain it in their reasoning as the trial an insurer makes them document, so part of what looks like a clinical rule is really a payer's rule that doctors have taken on as their own. That reading comes from the reasoning, not from a counted answer, so treat it as a lead, not a figure.

03Why does nobody hesitate in the case, yet two in three say they hold off?

We described one patient three times, each time with one more problem: eight weeks of correct topical use with flares every two to three weeks, then itch waking them most nights, then flares on both hands that make work difficult. At every step all 127 dermatologists said they were likely or very likely to start a systemic at that visit. The share saying very likely rose from 78.0% to 94.5% to 98.4%, so sleep loss is the step that moves the most people, but the panel was already at the ceiling before the first extra problem was added.

Set that beside the 66.1% (n=127) who say insurance requirements or prior authorization is what most often makes them hold off. The case said nothing about coverage. Clinically the decision is made by eight weeks; what stands between the decision and the first dose is paperwork.

04How does this fit with what dermatologists said about choosing a systemic?

In September a Brox panel of US dermatologists put safety first when choosing which systemic to start, and said coverage overrides that choice for about half of starts (read that page). Today only 3.1% (4 of 127) say safety or monitoring is what delays the move itself. Safety shapes which medicine a patient gets; it rarely decides whether they step up at all. Coverage shows up in both decisions.

05What would a brand or market access team do with this?

  1. A reading, not the panel's answer: the faster route to more systemic starts in moderate eczema is shortening the prior authorization step, not persuading dermatologists that a patient is ready.
  2. A reading, not the panel's answer: messages about sleep speak to the four in ten who escalate on itch and sleep, while evidence of a documented topical failure speaks to the half who escalate on the trial, and to the insurer behind it.
  3. Patient reluctance about an injection or a daily tablet is the second brake, named by 23.6% (n=127), and it is the one a clinic conversation can change.

Section 06: What they said, and the interview line it rests on

“Hands down, what most often makes me hold off on starting a systemic treatment is insurance requirements and the prior authorization process. Even when a patient with moderate atopic dermatitis is struggling and clearly not controlled on topicals, payers require us to jump through exhaustive hoops. You have to document step therapy—showing they've tried and failed multiple topical steroids or calcineurin inhibitors—just to get anything approved. We spend an enormous amount of time dealing with prior auths, appeals, and peer-to-peers, and if insurance denies coverage, we're forced to stay on or fall back to their mandated treatment ladder before we can ever get an advanced systemic in hand.”

Predicted from this line in the interview

“It's usually spending a lot of time dealing with the prior auths and appeals and ultimately insurance just will not cover. Therefore, the patient is unable to get started on it.”

Dermatologist, woman, 45-64, Texas supports finding 1

“For me, the tipping point is definitely itch or sleep loss affecting daily life. When moderate eczema patients aren't controlled on topicals, my trigger to step up to a systemic therapy is whether the disease is actively disrupting their sleep—having trouble falling or staying asleep—or if the persistent itch is interfering with their ability to work, study, or carry out meaningful daily activities.”

Predicted from this line in the interview

“Usually if patients are having difficulty sleeping at night, if it's causing them any difficulty to fall or stay asleep, or if it's impacting their ability to study or work or do any sort of daily life activities that are meaningful for them.”

Dermatologist, man, 30-44, Indiana supports finding 2

“For me, the main factor that decides moving a patient to a systemic treatment is having failed an adequate trial of both topical steroids and non-steroidal topicals like topical calcineurin inhibitors. Both from a clinical standpoint and practically speaking with insurance requirements, we have to document that a patient has done a solid trial of both—usually around three months—while making lifestyle modifications, and is still struggling or not achieving adequate control before we can escalate to a biologic or systemic therapy.”

Predicted from this line in the interview

“I think patients who aren't improving with topical therapies, those who are doing all the lifestyle changes well and still struggling after a good trial of both topical steroids and calcineurin inhibitors kind of trigger that.”

Dermatologist, woman, under 30, Indiana supports finding 2

Section 07: How much should you trust this?

What we would defend

  • Insurance and prior authorization as the commonest brake on the step up: 84 of 127, almost three times the next reason (30 of 127), and consistent with what a separate dermatologist panel said about coverage in September 2026.
  • The near-even split of the trigger between a failed topical trial (65 of 126) and itch or sleep loss (54 of 126).
  • Safety as a rare reason for delay: 4 of 127.

What we would not

  • Any size for the step from one rung of the case to the next: all 127 were likely or very likely at every rung, so the rise from 78.0% to 98.4% very likely is direction only.
  • The reading that the failed topical trial is largely an insurer's rule: it comes from the clones' reasoning, not from a counted answer.
  • Any split by practice type, region or years in practice: no segment breakdown was run on this study.

The main limitation

These are single picks of the reason that applies most often, from clones of US dermatologists; they show which reason dominates, not how often each one applies, and the case questions mention no insurance at all.

Section 08: How was this run?

Panel composition
SegmentClones
Manage adults with atopic dermatitis regularly122
Manage adults with atopic dermatitis occasionally5

Question wording as fielded

  1. Do you personally manage adult patients with atopic dermatitis (eczema) in your practice?
  2. When an adult with moderate atopic dermatitis is not controlled on topical treatment, which ONE factor most often decides that you move them to a systemic treatment?
  3. A 34-year-old adult with moderate atopic dermatitis on the arms and neck has used a mid-potency topical steroid and a non-steroidal topical correctly for eight weeks and still flares every two to three weeks. How likely are you to start a systemic treatment at this visit, on a scale of 1 (very unlikely) to 5 (very likely)?
  4. A 34-year-old adult with moderate atopic dermatitis on the arms and neck has used a mid-potency topical steroid and a non-steroidal topical correctly for eight weeks, still flares every two to three weeks, and says the itch wakes them on most nights. How likely are you to start a systemic treatment at this visit, on a scale of 1 (very unlikely) to 5 (very likely)?
  5. A 34-year-old adult with moderate atopic dermatitis on the arms and neck has used a mid-potency topical steroid and a non-steroidal topical correctly for eight weeks, still flares every two to three weeks, says the itch wakes them on most nights, and now has flares on both hands that make their work difficult. How likely are you to start a systemic treatment at this visit, on a scale of 1 (very unlikely) to 5 (very likely)?
  6. What most often makes you hold off on a systemic treatment for an adult with moderate atopic dermatitis who is not fully controlled on topicals?

What was not asked, and why

No question named a medicine or a brand, and none asked about cost to the patient, phototherapy, or children; the case asked about starting a systemic at the visit, not which one.

What changed from the obvious question

The obvious question asks what triggers the step up. This study also asked what holds it back, and put one patient through three stacked versions of the same case, so the page can set the clinical decision beside the thing that delays it.

Fielded through Ask Brox on 7 October 2026.

Ask this of your own customers: humans@brox.ai

Related insights

All in this topic